Lipocine (NASDAQ:LPCN) Stock Passes Below Two Hundred Day Moving Average – What’s Next?

Lipocine Inc. (NASDAQ:LPCN)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.10 and traded as low as $2.09. Lipocine shares last traded at $2.14, with a volume of 29,153 shares.

Wall Street Analyst Weigh In

LPCN has been the topic of a number of analyst reports. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Stock Performance

The stock’s 50-day simple moving average is $2.29 and its two-hundred day simple moving average is $5.06. The stock has a market cap of $17.07 million, a price-to-earnings ratio of -1.10 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. As a group, research analysts predict that Lipocine Inc. will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Lipocine

Large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new stake in shares of Lipocine in the 1st quarter worth approximately $998,000. Stempoint Capital LP bought a new position in Lipocine in the first quarter worth $1,282,000. ADAR1 Capital Management LLC bought a new position in Lipocine in the first quarter worth $185,000. Eversept Partners LP acquired a new stake in Lipocine during the first quarter worth $2,357,000. Finally, Exome Asset Management LLC acquired a new stake in Lipocine during the first quarter worth $486,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.